SEC Form 4 · accession 0001209191-15-042025
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daphne Quimi
Officer — VP Finance and Controller
Period of report
May 8, 2015
Accepted (ET)
May 12, 2015 · 9:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | May 8, 2015 | M | 25,000 | — | A | 25,000 | D | |
| Common stock | May 8, 2015 | F | 9,312 | $10.80 | D | 15,688 | D | |
| Common stockF3 | May 11, 2015 | S | 7,500 | $10.8408 | D | 8,188 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted stock unitsF1,F4 | — | May 8, 2015 | M | 25,000 | D | — | — | Common stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Restricted stock units convert into common stock on a one-for-one basis.
- F2The sales of shares of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2014.
- F3This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.72 to $10.90. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4On April 10, 2014, the reporting person was granted 50,000 restricted stock units, vesting in equal installments of 25,000 restricted stock units on May 10, 2015 and 25,000 restricted stock units on December 3, 2015.